 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
With Three Years of Cash in the Bank, Regulus Aims for Two INDs by 2014
November 29, 2012
With Three Years of Cash in the Bank, Regulus Aims for Two INDs by 2014
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Mirna Closes $34.5M Series C Round as microRNA Drugs Gain Investor Interest
October 25, 2012 / Gene Silencing News - In 2012, Top microRNA Drug Developers Pull in Nearly $150M in Funding
December 20, 2012 / Gene Silencing News - Regulus Inks microRNA Drugs Collaboration with AstraZeneca
August 16, 2012 / Gene Silencing News - As Evidence Grows for Role of microRNAs in Disease, Drugmakers Focus on Select Targets
December 16, 2010 / Gene Silencing News - Regulus Prices IPO at $4 a Share
October 4, 2012 / Gene Silencing News